Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial ...
Alliance said the results validate the study's assumptions, allowing it to move to the financing and development phase for the project. The firm is currently working on negotiating funding and offtake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback